NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

TerminatedPhase 2

Sponsor: RAPT Therapeutics, Inc.

Conditions: Asthma

Interventions: RPT193, Placebo

Countries: United States, Bulgaria, Czechia, Poland

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Physician diagnosis of asthma for ≥6 months
* Pre-bronchodilator FEV1 of \>40% and \<80%
* History of treatment with corticosteroid or hospitalization for worsening asthma
* Medium- or high-dose inhaled corticosteroid use

Exclusion Criteria:

* History of smoking/vaping
* History of severe COVID
* Serious and/or uncontrolled pulmonary, cardiac, immune system conditions
* Requires systemic oral or IV corticosteroids in the month prior to screening

Locations (29)

San Jose, California, United States
Stockton, California, United States
Westminster, California, United States
Aurora, Colorado, United States
Miami, Florida, United States
Miami, Florida, United States
Miami Lakes, Florida, United States
Tampa, Florida, United States
Edmond, Oklahoma, United States
Grants Pass, Oregon, United States
El Paso, Texas, United States
McKinney, Texas, United States
Greenfield, Wisconsin, United States
Kozloduy, Bulgaria
Sofia, Bulgaria
Sofia, Bulgaria
Stara Zagora, Bulgaria
Varna, Bulgaria
Vratsa, Bulgaria
Jindřichův Hradec, Czechia
Warsaw, Solipska, Poland
Bialystok, Poland
Krakow, Poland
Lodz, Poland
Lubin, Poland
Piotrkow Trybunalski, Poland
Poznan, Poland
Wroclaw, Poland
Wroclaw, Poland